Citi Downgrades Synergy Pharmaceuticals (SGYP) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Synergy Pharmaceuticals (SGYP) and its 'Poop Troop' are Oversold - BTIG
April 7, 2017 1:57 PM EDTBTIG analyst Timothy Chiang weighed in on Synergy Pharmaceuticals (NASDAQ: SGYP) after yesterday's "Poop Troop" news and competitor downgrade. Chiang views shares as oversold, and not reflecting the value of its recently launched Trulance product.
Chiang sees visibility on Trulance continuing to increase,... More
